Navigation Links
Combined treatment extends life expectancy for lung cancer patients

Combining thermal ablation with radiation therapy extends average life expectancy and decreases recurrences of tumors in patients who have early stages of inoperable lung cancer, according to researchers at Rhode Island Hospital.

In a retrospective study looking at patients over seven years, the median survival rate at three years increased from 20 months after radiation alone to 42 months when thermal ablation was followed by radiation for treatment of non-small-cell lung cancer. The results are published in the July issue of the Journal of Vascular and Interventional Radiology.

"This study shows us that even patients who are not eligible for surgery can still get very good results," says senior author Damian Dupuy, MD, director of ultrasound at Rhode Island Hospital and professor of diagnostic imaging at Brown Medical School, both in Providence, RI. "By combining thermal ablation and radiation, you have a better chance of survival than with either treatment alone."

With radiation alone, overall survival rates were as follows:

one year ?57 percent
two years ?36 percent
three years ?21 percent

With thermal ablation and radiation, they were significantly higher:

one year ?87 percent
two years ?70 percent
three years ?57 percent

Surgery is the standard treatment for lung cancer. However, only one-third of patients with early stage lung cancer qualify for surgery because of other underlying medical conditions. Radiation therapy has long been used for inoperable lung cancer, and more recently, doctors have used radiofrequency ablation (RFA) and microwave ablation, processes that heat tumors to destroy them. For patients who cannot have surgery or radiation, the median survival is about one year.

In this study, researchers looked retrospectively at 41 patients treated over seven years with thermal ablation (RFA or microwave ablation) and either standard radiation therapy or b rachytherapy, a procedure in which a "seed" of radioactive material is implanted into the cancer or near it. Patients were diagnosed with Stage I or II lung cancer, meaning the lung cancer in most cases had not spread and was usually smaller than 3 centimeters, though not in all cases. While this study did not address the timing of combined treatment, brachytherapy radiation was typically administered within two hours of thermal ablation while external beam radiation was given within three to four weeks. Rhode Island Hospital may be the only hospital in the world to administer this combined treatment.

The recurrence rate was much lower with the combined treatment. With radiation therapy alone, about 50 percent of tumors recur within six to 12 months. By the end of this study, 24 percent of patients treated with ablation and radiation had recurrences at an average of 44 months. While there was an increased recurrence rate in larger tumors ?33 percent recurred at an average of 34 months ?the overall survival rate was the same for patients with large and small tumors.

"We found that just because the tumor returns, that doesn't mean the patient lives less long," Dupuy says.

The combined treatments work because they create a "synergy," the authors write. When tumors are targeted with radiation therapy, oxygen is vital to help the radiation damage DNA and kill cancerous cells. While radiation is most effective in destroying cells around the edges of the tumor, it is less effective at targeting the center of the tumor, which tends to be a low-oxygen environment.

Thermal ablation, on the other hand, heats the tumor to kill cancerous cells ?reaching the center of the tumor, but not necessarily killing all the cells at the edges. This can lead to a recurrence of the tumor, and the cancer may spread. Thermal ablation is delivered directly to cancerous cells with the guidance of a diagnostic image showing the tumor's location. However, if som e cancerous cells have spread into small channels of the lung around the tumor, they tend to be small and not visible on a radiology scan. Thermal ablation, which sends electrical current into the tumor, may not penetrate far enough into the lung to kill these areas of cancer.

When the two therapies are combined, they complement each other. Thermal ablation kills the central tumor. In exchange, radiation kills the cells on the periphery of the tumor and elsewhere in the lung that are missed by thermal ablation.

While this study looked only at lung cancer, Dupuy also has pioneered the use of RFA in thyroid, kidney, adrenal and bone cancer. The combined treatment may have far-reaching effects, Dupuy says.

"You might be able to treat tumors elsewhere in the body with similar results," Dupuy says. "There are a lot of opportunities for exploring the synergy of thermal ablation and radiation."



Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
3. Protein discovery could unlock the secret to better TB treatment
4. Topical treatment shown to inhibit HIV and herpes simplex virus infection
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. Researchers add new tool to tumor-treatment arsenal
7. Potential treatments for neurofibromatosis
8. Nanoparticles offer new hope for detection and treatment
9. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
10. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
11. New understanding of DNA repair may pave way to cancer treatments
Post Your Comments:

(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... ... , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas Fertility Center as ... lab procedures as well as continue his research efforts into the emerging technologies of ... New Zealand to bring home a High Complexity Clinical Laboratory Director named Tex,” says ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
(Date:11/30/2015)... Spherix Incorporated (Nasdaq: SPEX ) an ... and monetization of intellectual property, today provided an ... to create shareholder value. Anthony ... on published reports, the total addressable market of ... Spherix will seek to secure fair and reasonable ...
Breaking Biology Technology: